Macquarie Group LTD Arvinas, Inc. Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $11,765 - $16,295	-281 Reduced 19.37%	1,170 $92,000
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $15,549 - $21,045	-258 Reduced 15.1%	1,451 $98,000
Q4 2021 Feb 11, 2022	BUY	$65.85 - $96.21 $18,701 - $27,323	284 Added 19.93%	1,709 $140,000
Q2 2021 Aug 13, 2021	BUY	$60.45 - $84.26 $49,629 - $69,177	821 Added 135.93%	1,425 $110,000
Q1 2021 May 14, 2021	SELL	$58.19 - $91.37 $16,642 - $26,131	-286 Reduced 32.13%	604 $40,000
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $11,568 - $48,664	573 Added 180.76%	890 $76,000
Q2 2020 Aug 11, 2020	BUY	$29.88 - $56.74 $9,471 - $17,986	317 New	317 $11,000

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.